...in the brain compared with vehicle control. Next steps include safety studies on similar compounds. Satori Pharmaceuticals Inc.... ...et al. J. Exp. Med.; published online Oct. 3, 2012; doi:10.1021/jm300976b Contact: Jed L. Hubbs, Satori Pharmaceuticals Inc....
...of motor symptoms in PD-and thus guide treatment decisions, he said. Barbara Tate, VP at Satori Pharmaceuticals Inc.... ...behavior is often used to measure cognition, said Jo Ann Dumin, principal research investigator at Satori... ...patient population, that could save a lot of time and money," she said. This year, Satori...
...Bridge to acquisition First generation gamma secretase inhibitors didn't work in Alzheimer's disease, but Satori Pharmaceuticals Inc. is... ...more selective gamma secretase modulator will not have the toxicity of previous compounds. Last week, Satori... ...two other existing investors: New Enterprise Associates and Prospect Venture Partners. InterWest started investing in Satori...
Satori Pharmaceuticals Inc. , Cambridge, Mass. Business: Neurology Appointed: Donald Hayden, a director, as chairman; Stephen Muniz, partner at PureTech Ventures; and David Schnell, co-founder and managing director of Prospect Venture Partners
WIR Staff
Neurology...
...Alzheimer's disease company Satori Pharmaceuticals Inc. (Cambridge, Mass.) raised $15 million in a financing co-led by existing investors... ...a financing co-led by existing investors InterWest Partners; New Enterprise Associates; and Prospect Venture Partners. Satori... ...Stephen Muniz and Prospect Venture's David Schnell joined Satori's board. PureTech is an existing investor. Satori...
...less toxic or perhaps beneficial, including beta amyloid 38, 39 and 40. This is what Satori Pharmaceuticals Inc.... ...itself without affecting the whole pool" of other gamma secretase substrates, said CEO Jeff Ives. Satori... ...secretase. This may mean other gamma secretase substrates are likely to be left undisturbed by Satori's...
...in the brain compared with vehicle control. Next steps include safety studies on similar compounds. Satori Pharmaceuticals Inc.... ...et al. J. Exp. Med.; published online Oct. 3, 2012; doi:10.1021/jm300976b Contact: Jed L. Hubbs, Satori Pharmaceuticals Inc....
...of motor symptoms in PD-and thus guide treatment decisions, he said. Barbara Tate, VP at Satori Pharmaceuticals Inc.... ...behavior is often used to measure cognition, said Jo Ann Dumin, principal research investigator at Satori... ...patient population, that could save a lot of time and money," she said. This year, Satori...
...Bridge to acquisition First generation gamma secretase inhibitors didn't work in Alzheimer's disease, but Satori Pharmaceuticals Inc. is... ...more selective gamma secretase modulator will not have the toxicity of previous compounds. Last week, Satori... ...two other existing investors: New Enterprise Associates and Prospect Venture Partners. InterWest started investing in Satori...
Satori Pharmaceuticals Inc. , Cambridge, Mass. Business: Neurology Appointed: Donald Hayden, a director, as chairman; Stephen Muniz, partner at PureTech Ventures; and David Schnell, co-founder and managing director of Prospect Venture Partners
WIR Staff
Neurology...
...Alzheimer's disease company Satori Pharmaceuticals Inc. (Cambridge, Mass.) raised $15 million in a financing co-led by existing investors... ...a financing co-led by existing investors InterWest Partners; New Enterprise Associates; and Prospect Venture Partners. Satori... ...Stephen Muniz and Prospect Venture's David Schnell joined Satori's board. PureTech is an existing investor. Satori...
...less toxic or perhaps beneficial, including beta amyloid 38, 39 and 40. This is what Satori Pharmaceuticals Inc.... ...itself without affecting the whole pool" of other gamma secretase substrates, said CEO Jeff Ives. Satori... ...secretase. This may mean other gamma secretase substrates are likely to be left undisturbed by Satori's...
